1 rich Libsyn https://www.libsyn.com 300 600 A thoughtful, practice-shaping study in NEJM explores a long-standing clinical dilemma: can we truly move the needle in post-thrombotic syndrome? &amp;nbsp; The C-TRACT trial shows that endovascular therapy (iliac-vein stenting) significantly improves symptom burden and quality of life in patients with moderate–severe disease—measured rigorously using VCSS, VEINES-QOL, and SF-36. The magnitude of benefit is clinically meaningful. &amp;nbsp; But every intervention casts a shadow. &amp;nbsp; 👉 Bleeding risk was ~3-fold higher, largely driven by intensified antithrombotic therapy. 👉 Durability beyond 6 months remains unknown. &amp;nbsp; This is not a simple “yes or no” trial—it is a study in nuance, trade-offs, and patient-centered decision making. &amp;nbsp; For the right patient—severe symptoms, clear iliac obstruction, acceptable bleeding risk—EVT may offer a path from limitation to liberation. &amp;nbsp; The vein opens. The patient breathes. The clinician pauses. &amp;nbsp; Science advances not in absolutes—but in balance. ⚖️🩺 Dr. RR Baliga's 'Podkast for the Kurious Doc' http://www.MasterMedFacts.com <iframe title="Libsyn Player" style="border: none" src="//html5-player.libsyn.com/embed/episode/id/40929365/height/300/theme/custom/thumbnail/yes/direction/forward/render-playlist/no/custom-color/88AA3C/" height="300" width="600" scrolling="no" allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen></iframe> https://assets.libsyn.com/secure/content/200956345